CO2023003282A2 - Nuevos derivados de psilocina que tienen propiedades de profármaco - Google Patents
Nuevos derivados de psilocina que tienen propiedades de profármacoInfo
- Publication number
- CO2023003282A2 CO2023003282A2 CONC2023/0003282A CO2023003282A CO2023003282A2 CO 2023003282 A2 CO2023003282 A2 CO 2023003282A2 CO 2023003282 A CO2023003282 A CO 2023003282A CO 2023003282 A2 CO2023003282 A2 CO 2023003282A2
- Authority
- CO
- Colombia
- Prior art keywords
- psilocin
- derivatives
- new
- prodrug properties
- prodrug
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102020121965.2A DE102020121965A1 (de) | 2020-08-21 | 2020-08-21 | Neuartige Derivate des Psilocins mit Prodrug-Eigenschaften |
| US202063118842P | 2020-11-27 | 2020-11-27 | |
| PCT/EP2021/073303 WO2022038299A1 (en) | 2020-08-21 | 2021-08-23 | Novel psilocin derivatives having prodrug properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023003282A2 true CO2023003282A2 (es) | 2023-04-17 |
Family
ID=77739049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0003282A CO2023003282A2 (es) | 2020-08-21 | 2023-03-16 | Nuevos derivados de psilocina que tienen propiedades de profármaco |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230295086A1 (https=) |
| EP (1) | EP4200279A1 (https=) |
| JP (1) | JP2023538402A (https=) |
| KR (1) | KR20230054397A (https=) |
| CN (2) | CN116075499B (https=) |
| AU (1) | AU2021328726A1 (https=) |
| BR (1) | BR112023003153A2 (https=) |
| CA (1) | CA3188636A1 (https=) |
| CO (1) | CO2023003282A2 (https=) |
| GB (2) | GB2632056B (https=) |
| IL (1) | IL300455A (https=) |
| MX (1) | MX2023002133A (https=) |
| WO (1) | WO2022038299A1 (https=) |
| ZA (1) | ZA202301693B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11974984B2 (en) | 2017-02-09 | 2024-05-07 | Caamtech, Inc. | Compositions and methods comprising a combination of serotonergic drugs |
| US12414936B2 (en) * | 2017-02-09 | 2025-09-16 | Caamtech, Inc. | Compositions comprising a serotonergic tryptamine compound |
| CN114787363A (zh) | 2019-10-01 | 2022-07-22 | 恩派瑞安神经科学公司 | 对真菌进行遗传工程化以调节色胺表达 |
| PH12022551981A1 (en) | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| WO2022120181A1 (en) * | 2020-12-03 | 2022-06-09 | Mydecine Innovations Group Inc. | Novel psilocin analog compositions and methods of synthesizing the same |
| US12343328B2 (en) | 2020-12-09 | 2025-07-01 | Caamtech, Inc. | Dialkyl tryptamines and their therapeutic uses |
| US12534441B2 (en) | 2021-01-15 | 2026-01-27 | Beckley Psytech Limited | Tryptamine analogues |
| EP4126857A1 (en) | 2021-01-15 | 2023-02-08 | Beckley Psytech Limited | Ergoline analogues |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| WO2023023347A1 (en) * | 2021-08-20 | 2023-02-23 | Terran Biosciences Inc. | Prodrugs and derivatives of psilocin and uses thereof |
| EP4452939A4 (en) * | 2021-12-24 | 2025-12-10 | Kuleon Llc | SEROTONINERGIC COMPOUNDS, POLYPODS, AND PROMEDICINAL PRODIGITS OF SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS |
| EP4457336A4 (en) | 2021-12-31 | 2026-01-14 | Empyrean Neuroscience Inc | ORGANISMS GENETICALLY MODIFIED TO PRODUCE PSYCHOTROPIC ALKALOIDS |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| US12065404B2 (en) | 2022-03-18 | 2024-08-20 | Enveric Biosciences Canada Inc. | C4-carboxylic acid-substituted tryptamine derivatives and methods of using |
| US11707447B1 (en) | 2022-03-18 | 2023-07-25 | Enveric Biosciences Canada Inc. | C4-carbonothioate-substituted tryptamine derivatives and methods of using |
| EP4493544A4 (en) * | 2022-03-18 | 2026-03-04 | Enveric Biosciences Canada Inc | TRYPTAMINE DERIVATIVE SALTS SUBSTITUTED WITH C4-CARBOXYLIC ACID AND C4-CARBONOTHIOATE AND METHODS OF USE |
| WO2023201293A2 (en) * | 2022-04-13 | 2023-10-19 | Caamtech, Inc. | Tryptamine derivatives |
| EP4522167A1 (en) * | 2022-05-10 | 2025-03-19 | Mydecine Innovations Group Inc. | Novel psilocin prodrug compounds and methods of synthesizing the same |
| WO2023219789A1 (en) * | 2022-05-10 | 2023-11-16 | Mydecine Innovations Group Inc. | Novel psilocin prodrug compounds and methods of synthesizing the same |
| JP2025527296A (ja) * | 2022-08-05 | 2025-08-20 | マインドセット ファーマ インコーポレイテッド | セロトニンに関する障害の治療に有用であるセロトニン作動薬としての３－エチルアミノ－インドール二量体 |
| CA3261814A1 (en) * | 2022-08-05 | 2024-02-08 | Mindset Pharma Inc. | 3-PYRROLIDINE-INDOLE DIMERS USED AS SEROTONINERGY AGENTS USEFUL FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH THESE |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| WO2024055106A1 (en) * | 2022-09-12 | 2024-03-21 | Bionxt Solutions Inc. | Amino acid and carbohydrate psilocin derivatives |
| US20240269113A1 (en) * | 2023-01-24 | 2024-08-15 | Compass Pathfinder Limited | 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| EP4592276A1 (en) | 2024-01-29 | 2025-07-30 | Universität Heidelberg | Novel acyloxymethyl prodrugs of psilocin and related 4-hydroxytryptamines obtained by an efficient synthetic approach |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3075992A (en) | 1958-09-12 | 1963-01-29 | Sandoz Ltd | Esters of indoles |
| CH386442A (de) | 1959-03-18 | 1965-01-15 | Ciba Geigy | Verfahren zur Herstellung neuer 7-Aza-benzimidazole |
| AU2005300045A1 (en) * | 2004-09-27 | 2006-05-04 | Organix, Inc. | Indole compounds useful as serotonin selective agents |
| JP2010507585A (ja) * | 2006-10-19 | 2010-03-11 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 置換インドール |
| US20180021326A1 (en) * | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
| CA3052974A1 (en) * | 2017-02-09 | 2018-08-16 | CaaMTech, LLC | Compositions and methods comprising a psilocybin derivative |
| PH12022551981A1 (en) * | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| WO2023023347A1 (en) * | 2021-08-20 | 2023-02-23 | Terran Biosciences Inc. | Prodrugs and derivatives of psilocin and uses thereof |
| US20240269113A1 (en) * | 2023-01-24 | 2024-08-15 | Compass Pathfinder Limited | 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES |
| US20250066394A1 (en) * | 2023-08-25 | 2025-02-27 | Compass Pathfinder Limited | 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES |
-
2021
- 2021-08-23 GB GB2412449.7A patent/GB2632056B/en active Active
- 2021-08-23 CN CN202180051296.8A patent/CN116075499B/zh active Active
- 2021-08-23 AU AU2021328726A patent/AU2021328726A1/en active Pending
- 2021-08-23 EP EP21769676.4A patent/EP4200279A1/en active Pending
- 2021-08-23 IL IL300455A patent/IL300455A/en unknown
- 2021-08-23 GB GB2304067.8A patent/GB2613993B/en active Active
- 2021-08-23 BR BR112023003153A patent/BR112023003153A2/pt unknown
- 2021-08-23 US US18/021,243 patent/US20230295086A1/en active Pending
- 2021-08-23 CN CN202510790017.XA patent/CN120904096A/zh active Pending
- 2021-08-23 WO PCT/EP2021/073303 patent/WO2022038299A1/en not_active Ceased
- 2021-08-23 JP JP2023512327A patent/JP2023538402A/ja active Pending
- 2021-08-23 KR KR1020237008542A patent/KR20230054397A/ko active Pending
- 2021-08-23 CA CA3188636A patent/CA3188636A1/en active Pending
- 2021-08-23 MX MX2023002133A patent/MX2023002133A/es unknown
-
2023
- 2023-02-10 ZA ZA2023/01693A patent/ZA202301693B/en unknown
- 2023-03-16 CO CONC2023/0003282A patent/CO2023003282A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB2632056A (en) | 2025-01-22 |
| WO2022038299A1 (en) | 2022-02-24 |
| EP4200279A1 (en) | 2023-06-28 |
| GB202412449D0 (en) | 2024-10-09 |
| JP2023538402A (ja) | 2023-09-07 |
| GB2613993A (en) | 2023-06-21 |
| ZA202301693B (en) | 2026-01-28 |
| IL300455A (en) | 2023-04-01 |
| GB2613993B (en) | 2024-10-09 |
| MX2023002133A (es) | 2023-05-12 |
| GB2632056B (en) | 2025-04-16 |
| AU2021328726A1 (en) | 2023-03-02 |
| CN120904096A (zh) | 2025-11-07 |
| KR20230054397A (ko) | 2023-04-24 |
| BR112023003153A2 (pt) | 2023-04-04 |
| US20230295086A1 (en) | 2023-09-21 |
| CN116075499B (zh) | 2025-07-25 |
| CA3188636A1 (en) | 2022-02-24 |
| CN116075499A (zh) | 2023-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023003282A2 (es) | Nuevos derivados de psilocina que tienen propiedades de profármaco | |
| DOP2022000124A (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| ECSP088623A (es) | Derivados de azepinoindol como agentes farmacéuticos | |
| GT201300174A (es) | Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme) | |
| UY35273A (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn | |
| MX392270B (es) | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. | |
| MX420195B (es) | Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos | |
| MX376833B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| PA8680701A1 (es) | Derivados de oxindol | |
| UY37182A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| MX382122B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| CR20190257A (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
| BR112016030733A2 (pt) | Derivados de indano e indolina e uso dos mesmos como ativadores de guanilato ciclase solúveis | |
| CO2019002618A2 (es) | Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos | |
| AR111176A1 (es) | Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos | |
| AR046756A1 (es) | Derivados de hidronopol como agonistas de receptores orl-1 humanos. | |
| CY1122321T1 (el) | Παραγωγα φθοροϊνδολιου ως θετικοι αλλοστερικοι διαμορφωτες του μουσκαρινικου υποδοχεα μ1 | |
| AR065348A1 (es) | Composicion farmaceutica que comprende un agonista no peptidico del receptor de tpo, combinacion farmaceutica con un agente anti-neoplasico y sus usos para preparar un medicamento tratamiento del cancer | |
| MX2018008157A (es) | Alfa-amino esteres de derivado de hidroxipropiltiazolidin carboxamida, y formas de sales y polimorfos cristalinos de estos. | |
| CY1123185T1 (el) | Παραγωγα ινδολιου | |
| MX2022000099A (es) | Compuestos para el tratamiento del cancer. | |
| DOP2007000121A (es) | Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para su preparación, medicamentos que comprenden estos compuestos y su uso | |
| ECSP19084722A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| CL2019000727A1 (es) | Compuestos de indazol para usar en lesiones de tendones y/o ligamentos. |